Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP326408.RAUZ44I0M4b0KLsE5owAboj0euxn_8jzrZU9ibdo46YhA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP326408.RAUZ44I0M4b0KLsE5owAboj0euxn_8jzrZU9ibdo46YhA130_assertion type Assertion NP326408.RAUZ44I0M4b0KLsE5owAboj0euxn_8jzrZU9ibdo46YhA130_head.
- NP326408.RAUZ44I0M4b0KLsE5owAboj0euxn_8jzrZU9ibdo46YhA130_assertion description "[The high incidence of CRF(1) or CRF(2) receptors in selected human tumors suggests that unlabeled CRF agonists may be evaluated as inhibitors of tumor cell proliferation in cancer therapy, and radiolabeled CRF analogs may be used for cancer diagnosis and/or radiotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP326408.RAUZ44I0M4b0KLsE5owAboj0euxn_8jzrZU9ibdo46YhA130_provenance.
- NP326408.RAUZ44I0M4b0KLsE5owAboj0euxn_8jzrZU9ibdo46YhA130_assertion evidence source_evidence_literature NP326408.RAUZ44I0M4b0KLsE5owAboj0euxn_8jzrZU9ibdo46YhA130_provenance.
- NP326408.RAUZ44I0M4b0KLsE5owAboj0euxn_8jzrZU9ibdo46YhA130_assertion SIO_000772 12843181 NP326408.RAUZ44I0M4b0KLsE5owAboj0euxn_8jzrZU9ibdo46YhA130_provenance.
- NP326408.RAUZ44I0M4b0KLsE5owAboj0euxn_8jzrZU9ibdo46YhA130_assertion wasDerivedFrom befree-20150227 NP326408.RAUZ44I0M4b0KLsE5owAboj0euxn_8jzrZU9ibdo46YhA130_provenance.
- NP326408.RAUZ44I0M4b0KLsE5owAboj0euxn_8jzrZU9ibdo46YhA130_assertion wasGeneratedBy ECO_0000203 NP326408.RAUZ44I0M4b0KLsE5owAboj0euxn_8jzrZU9ibdo46YhA130_provenance.